Company profile
LIGAND PHARMACEUTICALS INC
NASDAQ:LGNDBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Acyclovir | approved | — | 0 | — |
| Sparsentan | approved | — | 9 | approved |
| LGD-6972 | phase2 | — | 4 | no active trials |
| VK-2809 | phase2 | — | 3 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (21)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02672839 | phase1 | completed | 2016-02-01 | 2016-05-01 | Ligand Pharmaceuticals | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation |
| NCT00635232 | phase2 | completed | 2008-03-01 | 2008-11-01 | Ligand Pharmaceuticals | A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension |
| NCT02851849 | phase2 | completed | 2016-09-01 | 2017-06-01 | Ligand Pharmaceuticals | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus |
| NCT00002212 | phase2 | completed | — | — | Ligand Pharmaceuticals | A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma |
| NCT00522925 | phase2 | completed | 2007-08-01 | 2008-04-01 | Ligand Pharmaceuticals | A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 203791 | NDA | LIGAND PHARMACEUTICALS INC | ||||
Loading… | ||||||